-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...
More »SEARCH RESULT
Total Matching Records found : 382
SMS, RTI potent tools of drug companies fighting patent battle -Soma Das
-The Economic Times NEW DELHI: As patent wars heat up in the pharma space, mobile phone messages and Right to Information filings have emerged as potent weapons in the hands of multinationals keen to delay competition from low-cost generic versions of their patented products in India. Innovator drugmakers, who used to strike with patent suits after generic drugmakers released their versions in the market, have started gleaning information from text messages sent...
More »A flood of telegrams for PM urging an 'end to corruption' -Akshaya Mukul
-The Times of India NEW DELHI: It will be an unusual Monday morning in Prime Minister Manmohan Singh's household. Among the bagful of mail he gets daily will be several telegrams urging him to 'end corruption, give us freedom'. As the 160-year-old telegram service wound down on Sunday, one young man's idea of sending a telegram to the PM on corruption caught the fancy of others in the serpentine queue at the...
More »Kerala tackles prejudice and prices -C Maya
-The Hindu The State population stands at a little over three crore, but average consumption of drugs is three times the national average In Kerala, where people have a marked preference for branded drugs, where the most expensive brand is considered the best, and only those brands pushed by doctors sell, the new Drug (Prices Control) Order, which is expected to cut prices by 20-25 per cent, may not have much of...
More »Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan
-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »
